1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Global Antibiotics Market By Action Mechanism, By Drug Class, By Region, Industry Analysis and Forecast, 2020 - 2026

Global Antibiotics Market By Action Mechanism, By Drug Class, By Region, Industry Analysis and Forecast, 2020 - 2026

  • January 2021
  • 221 pages
  • ID: 6021874
  • Format: PDF
  • KBV Research
Up to $907 off Until Jul 31st 2021


Table of Contents

Search Inside

The Global Antibiotics Market size is expected to reach $62.5 billion by 2026, rising at a market growth of 5.3% CAGR during the forecast period. Antibiotic is a substance that fights against bacterial and protozoan infections. Additionally, they help in treating many diseases like urinary tract infections, pneumonia, strep throat, skin infections, sinus infections, ear infections and many more. Antibiotics can be classified on various bases but the most common classification is done on the basis of spectrum of activity, chemical structures, and mode of action. Presently, the demand for beta-lactam and beta-lactamase inhibitors class of antibiotics is more among healthcare providers.

The antibiotics market is growing owing to the increasing consumption of antibiotics in middle and lower-income countries, huge investments in R&D activities by pharmaceutical companies, and the increasing number of infectious diseases. Although, the development of antibiotic resistance and the rising cost of drug approval hinder the growth of the antibiotic market. On the other hand, advanced prospect molecules and the development of novel combination therapies to cure antibiotic-resistant microbial infections are estimated to propel the market and provide great opportunities for the market players.

The increased cases of infectious diseases in developing regions like the Asia Pacific and the Middle East are estimated to support the market growth. According to the data provided by WHO, above 15% of the children’s death is caused by pneumonia. Similarly, tuberculosis is more prevalent in the South Asian and Sub-Saharan regions. Presently, the much-needed antibiotic treatment is accessible only to one-third of the infected population that further expands the disease burden.

By Action Mechanism

Based on Action Mechanism, the market is segmented into Cell Wall Synthesis Inhibitors, Protein Synthesis Inhibitors, DNA Synthesis Inhibitors, RNA Synthesis Inhibitors, and Mycolic Acid Inhibitors. RNA and Folic acid synthesis inhibitors are expected to witness notable CAGRs during the forecast period. The evolutions of various antiviral drugs that inhibit transcription and reverse transcription processes are expected to help in the growth of the market. Folic acid inhibitor sulfa drugs are estimated to expand as they have a broad range of applications.

By Drug Class

Based on Drug Class, the market is segmented into Cephalosporin, Penicillin, Fluoroquinolone, Macrolides, Carbapenem, Aminoglycosides, Sulfonamides, and Others. The other antibiotics category includes imidazoles, tetracyclines, monoclonal antibodies, and lincosamides. It is expected that the other antibiotic category will expand at a high CAGR over the forecast period. The innovation of monoclonal antibodies for people who have developed antibiotic-resistance is the main feature of this category.

By Region

Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. North America continues to attain a high market share in the antibiotic market worldwide. The Healthcare System in North America helps in the utilization of branded products, although, with the loss of exclusivity of certain molecules, sales of the region have declined significantly in the last few years. Latin America, specifically Brazil, with its notable growth in the pharmaceuticals industry is also expected to boost the growth of the market. The outbreak of some viruses like Ebola in Africa is anticipated to push the growth of the market in this region.

The major strategies followed by the market participants are Acquisition and Partnerships. Based on the Analysis presented in the Cardinal matrix; Pfizer, Inc., Johnson and Johnson, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., and Novartis AG are some of the forerunners in the Antibiotics Market. Companies such as Sanofi S.A., Bayer AG, etc. are some of the key innovators in Antibiotics Market.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include GlaxoSmithKline PLC (GSK), Johnson and Johnson, Merck & Co., Inc., Pfizer, Inc., Bayer AG, Novartis AG, Sanofi S.A., Abbott Laboratories, F. Hoffmann-La Roche Ltd., and Eli Lilly and Company.

Strategies deployed in Antibiotics Market

Nov-2020: Merck & Co. introduced its novel antibiotic combination Recarbrio in the UK. The antibiotic cure infections caused by aerobic Gram-negative organisms in adults with finite treatment options.

Oct-2020: Pfizer agreed to acquire Arixa, a private real estate lender. The acquisition will help Pfizer to advance the development program for Arixa’s leading asset, ARX-1796. The potential benefits of ARX-1796 provide patients and the healthcare system and potentially enable patients to leave the hospital earlier or avoid the requirement for the hospital admission.

Aug-2020: Sanofi signed an agreement to acquire Principia Biopharma, a late-stage biopharmaceutical company. The acquisition will help Sanofi to expand its autoimmune disease drug line. It also helps in advancing their R&D transformation to boost the development of the most promising medicines that will address significant patient requirements.

Jul-2020: Novartis together with its biosimilars division Sandoz signed an agreement with the Austrian Federal Government. The agreement aimed to strengthen the long-term future of integrated antibiotics manufacturing in Europe.

Jun-2020: Roche came into partnership with SpeeDx Pty. Ltd., an Australian-based private company. The partnership is a significant inflection point for the company and enables more patients and clinicians around the world. It also allows access to the key diagnostic tools for the management of antibiotic resistance.

Apr-2020: Sanofi entered into a collaboration with GSK, a British multinational pharmaceutical company. The collaboration aimed to develop an adjuvanted vaccine for COVID-19, using innovative technology from both companies. This technology produced an exact genetic match to proteins found on the surface of the virus. The DNA sequence encodes this antigen, combined into the DNA of the baculovirus expression platform, the basis of Sanofi’s licensed recombinant influenza product in the US.

Mar-2020: La Roche entered into a collaboration with Forge Therapeutics, a biotechnology company. The collaboration aimed to license FG-LpxC LUNG, a novel antibiotic for curing serious lung infections attributed to antibiotic-resistant Gram-negative bacteria including Pseudomonas aeruginosa. The FG-LpxC LUNG program is developed to cure hospital-based infections, which include those cited on the CDC’s most urgent threats list that commonly occurs in people with weakened immune systems and chronic lung diseases.

Jan-2020: Sanofi took over Synthorx, a biotechnology company. This acquisition added on to its synthorin drugs for cancer and autoimmune indications to its pipeline. Synthorins are proteins that are altered by using a base pair technique to enhance their characteristics.

Dec-2019: Johnson & Johnson is acquiring Bermekimab from XBiotech Inc. Bermekimab is an anti-IL-1alpha monoclonal antibody (mAb) in Phase 2 development for curing atopic dermatitis and hidradenitis suppurativa. The acquisition will help the company to improve its ability to assist patients, providing their decades-long heritage and intense expertise in immunology.

Jul-2019: Merck & Co. announced the approval of Recarbrio by the FDA. Recarbrio is an injection antibiotic for adult patients with complicated urinary tract infections, or cUTIs, with limited or no treatment options. Along with that, it also cures adults with certain complicated intra-abdominal infections, or cIAIs, and which have limited or no treatment options.

Oct-2018: Novartis entered into an agreement with Boston Pharmaceuticals, a biopharmaceutical company. The agreement aimed to develop three novel anti-infective drug candidates, adding to the Novartis Infectious Diseases portfolio. The portfolio has the potential to address the requirement for new agents to cure antibiotic resistant Gram-negative infections.

Oct-2017: Roche partnered with Warp Drive Bio, a subsidiary of Revolution Medicines. The partnership focused on the development of new classes of antibiotics against multidrug-resistant bacterial infections. Together, they designed to advance multiple novel classes of natural antibiotics that show activity against clinically important, drug-resistant, Gram-negative pathogens by applying Warp Drive’s Genome Mining platform.

Mar-2017: Pfizer introduced Zavicefta, a novel combination antibiotic. Zavicefta treats patients with certain confirmed or suspected Gram-negative bacterial infections who needed hospitalization, available in the U.K. and Germany. Zavicefta was developed in response to the urgent medical requirement for new antibiotics for difficult-to-treat Gram-negative bacteria.

Jan-2017: Johnson & Johnson agreed to acquire Actelion Ltd, a pharmaceuticals and biotechnology company. The acquisition helped Actelion’s specialty in-market medicines and late-stage products compatible with Johnson & Johnson’s efforts to expand the attractive and complementary therapeutic areas and deliver patients with serious illnesses and significant unmet medical requirements.

Aug-2016: Pfizer acquired AstraZeneca’s development and commercialization rights to its late-stage small molecule anti-infectives business. The introduction of AstraZeneca’s complementary small molecule anti-infectives portfolio helped in expanding patient access to these important medicines. It also enhanced their global expertise and offerings in the important area of therapeutics. Additionally, they provide the opportunity for near-term revenue to grow.

Scope of the Study

Market Segments covered in the Report:

By Action Mechanism

• Cell Wall Synthesis Inhibitors

• Protein Synthesis Inhibitors

• DNA Synthesis Inhibitors

• RNA Synthesis Inhibitors,

• Mycolic Acid Inhibitors

By Drug Class

• Cephalosporin

• Penicillin

• Fluoroquinolone

• Macrolides

• Carbapenem

• Aminoglycosides

• Sulfonamides,

• Others

By Geography

• North America

o US

o Canada

o Mexico

o Rest of North America

• Europe

o Germany

o UK

o France

o Russia

o Spain

o Italy

o Rest of Europe

• Asia Pacific

o China

o Japan

o India

o South Korea

o Singapore

o Malaysia

o Rest of Asia Pacific


o Brazil

o Argentina


o Saudi Arabia

o South Africa

o Nigeria

o Rest of LAMEA

Companies Profiled

• GlaxoSmithKline PLC (GSK)

• Johnson and Johnson

• Merck & Co., Inc.

• Pfizer, Inc.

• Bayer AG

• Novartis AG

• Sanofi S.A.

• Abbott Laboratories

• F. Hoffmann-La Roche Ltd.

• Eli Lilly and Company

Unique Offerings

• Exhaustive coverage

• Highest number of market tables and figures

• Subscription based model available

• Guaranteed best price

• Assured post sales research support with 10% customization free

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
15% Off


  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Anti-Infective Agents Market Report 2021-2031

  • $ 5399
  • May 2021
  • 1125 pages

Forecasts by Type (Antiviral Infections, Antibacterial Infections, Antifungal Infections, Others), by Route of Administration (Topical, Oral, IV, Others), by Distribution Channel (Hospital Pharmacy, Retail ...

  • World
  • Anti-Infective
  • Industry analysis


Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on